EDMONTON, March 19, 2018 /CNW/ - Tevosol, Inc. ("Tevosol" or the "Company") today announces: (i) changes to its senior management team; (ii) additions to the Company's Advisory Board; and (iii) the beginning of the Company's first human Investigator Lead Trial ("ILT"). These changes are part of Company's milestone achievement of shifting its focus from the medical device design stage towards the clinical trial stage.
Management and Advisory Additions
Tevosol has appointed Dr. Darren Freed as the President and Interim Chief Executive Officer. Dr. Freed, a Co-Founder of the Company, will focus on leading Tevosol through the ILT and its next phase of financing.
Kevin Ens has been Tevosol's Chief Executive Officer since 2015. Commenting on the changes to the management team, Dr. Jayan Nagendran, a Tevosol Co-Founder and Director of Clinical Investigation said: "We are grateful to Kevin for his contributions to Tevosol through our critical early period of Tevosol's formation. He has been instrumental in leading Tevosol to reach its first major milestone in the pending ILT and has positioned the company for future success. We appreciate Kevin's commitment to ensuring a smooth transition and wish him well in his new endeavors."
The Company is also pleased to announce that Chris Jaynes and Dr. Kumud Dhital have joined the Tevosol Advisory Board. Mr. Jaynes brings over 15 years of experience working in the organ transplant space and has successfully lead companies through the device development process. Dr. Dhital is a senior cardiothoracic transplant surgeon with extensive experience in ex vivo organ perfusion including clinical trials.
Investigator Lead Trial
Tevosol's first in human clinical trial is being conducted at the University of Alberta Hospital in Edmonton, Alberta. The trial will test Tevosol's Negative Pressure Ventilation (NPV) technology in a limited number of patients to demonstrate safety and feasibility in support of lung transplantation. The data generated from the trial will support the next round of financing and evolution of the device to a form that will undergo multi-center clinical trials in preparation for an FDA submission.
Tevosol, Inc. is a medical device company developing the Ex-Vivo Organ Support System (EVOSS™) with the goal of increasing the number of organs available for transplantation. EVOSS™ is a portable warm perfusion device intended to achieve better recovery of organs, better resuscitation of dysfunctional organs, and longer preservation of function with the opportunity for ex-vivo treatment and evaluation. The system consists of a common hardware platform with organ-specific single-use disposable cassettes for lungs, hearts, livers and kidneys.
SOURCE Tevosol, Inc.
Renseignements: David Moon, 416-735-9091